Description
Adbry (tralokinumab-ldrm) is a prescription medication used to treat moderate to severe eczema in adults. It is classified as a biologic medication, specifically an interleukin-13 (IL-13) inhibitor.
Uses:
Adbry is used to treat moderate to severe eczema (atopic dermatitis) in adults who have failed to respond to other topical treatments or have severe disease requiring systemic therapy.
Storage conditions:
Adbry should be stored in a refrigerator at a temperature between 2°C to 8°C (36°F to 46°F). Do not freeze or shake the medication.
Mechanism of action:
Adbry works by inhibiting IL-13, an inflammatory protein that plays a major role in the development of eczema. It reduces inflammation, itching, and other symptoms of eczema by blocking the biological activity of IL-13.
HOW TO USE:
Adbry is given as a subcutaneous injection by a healthcare provider. Initially, two loading doses are given two weeks apart and then a maintenance dose is given every four weeks. Your doctor will determine the appropriate dose for you based on your medical history, age, weight, and response to treatment.
Precautions:
Before taking Adbry, inform your doctor if you have any infections, such as tuberculosis, hepatitis B or C, or have previously had them, or have a weakened immune system. Adbry can increase the risk of infections. Therefore, before starting Adbry, your doctor may need to screen you for these infections and monitor you during treatment.
Drug Interactions:
There are no known drug interactions between Adbry and other medications. However, it is important to inform your doctor of all the medications you are currently taking, including over-the-counter drugs and supplements.
Contraindications:
Adbry is contraindicated in patients who have hypersensitivity to tralokinumab or any of its components.
Overdose:
There is no specific antidote for Adbry overdose. If an overdose is suspected, seek medical attention immediately.
Adverse Reactions:
Common side effects of Adbry include injection site reactions, such as pain, redness, and swelling. These side effects are usually mild and resolve within a few hours to a few days. However, other serious adverse effects may occur, including anaphylaxis, which can occur immediately after administration and requires immediate medical attention. Other adverse reactions are hypersensitivity reactions, increased risk of infections, and conjunctivitis.
In conclusion, Adbry is an effective medication for the treatment of moderate to severe eczema in adults. It is administered as a subcutaneous injection by a healthcare provider and works by inhibiting the inflammatory protein interleukin-13. Patients should inform their doctor of any infections, including tuberculosis, hepatitis B or C, or weakened immune system. Injection site reactions are common side effects, while other serious adverse effects, including anaphylaxis and increased risk of infections, may occur.
Reviews
There are no reviews yet.